Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SG001 with nab-paclitaxel for advanced triple-negative breast cancer; efficacy and safety data not yet available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• SG001

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN